Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma
Óscar Arrieta, Zyanya Lucía Zatarain-Barrón, Jenny G. Turcott, Feliciano Barrón, Sai Yendamuri, Andrés F. Cardona, Rafael Rosell
Abstract
This secondary analysis reports the survival outcome in patients with EGFR variant-positive non–small-cell lung cancer who had a body mass index that was higher or lower than 24.
Topics & Concepts
MedicineMetforminEpidermal growth factor receptorInternal medicineTyrosine kinaseAdenocarcinomaOncologyLung cancerLungAdenocarcinoma of the lungRandomized controlled trialCancer researchCancerReceptorInsulinGastric Cancer Management and OutcomesLung Cancer Treatments and MutationsMetabolism, Diabetes, and Cancer